Abstracts Archive - Page 884 of 2425 - ACR Meeting Abstracts

Abstract Number: 1884 • 2019 ACR/ARP Annual Meeting
Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis
Ted Mikuls¹, Jess Edison ², Elizabeth Mewshaw ², Harlan Sayles ³, Geoffrey Thiele ¹, Michael Duryee ³, Carlos Hunter ³, LauraKay Moss ⁴, Marie Feser ⁵, Mark Parish ⁶ and Kevin Deane ⁵, ¹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ²Walter Reed National Military Medical Center, Bethesda, MD, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁶University of Colorado Denver, Aurora, CO
Background/Purpose: Previous work has demonstrated that malondialdehyde-acetalehyde (MAA) adducts, resulting from oxidative stress, are formed in synovial and lung tissues of patients with rheumatoid arthritis…
Abstract Number: 1885 • 2019 ACR/ARP Annual Meeting
A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
Xanthe ME Matthijssen¹, Fenne Wouters ², Debbie Boeters ², Aleid Boer ², Yousra Dakkak ², Ellis Niemantsverdriet ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Based on a unique cohort of clinically suspect arthralgia (CSA) patients, we analysed which combinations of MRI-features at onset were predictive for Rheumatoid Arthritis…
Abstract Number: 1886 • 2019 ACR/ARP Annual Meeting
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Thierry Dervieux¹, Joel Kremer ², John Conklin ¹, Kelley Brady ¹, Roberta Alexander ¹, Tyler O'Malley ³, Jing Shi ¹, Claudia Ibarra ¹, Michael Mahler ⁴, Michael Weinblatt ⁵ and Arthur Weinstein ¹, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Exagen, Oceanside, CA, ⁴Inova Diagnostics, San Diego, CA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Novel antibody systems including anti-carbamylated protein antibody (anti-CarP IgG) and anti-peptidyl arginine deiminase antibody (anti-PAD4 IgG) are emerging as independent diagnostic and prognostic biomarkers…
Abstract Number: 1887 • 2019 ACR/ARP Annual Meeting
Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Richard Moore¹, Tiffany Pan ¹, J. Lee Nelson ² and Christian Lood ¹, ¹University of Washington, Seattle, ²Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Mitochondria are key regulators of metabolism, inflammation and cell death, with mitochondrial dysfunction being associated with several diseases. Though mainly found intracellularly, we recently…
Abstract Number: 1888 • 2019 ACR/ARP Annual Meeting
Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
Emma de Moel¹, Jürgen Rech ², Michael Mahler ³, Johannes Roth ⁴, Anne Schouffoer ⁵, Karel Ronday ⁶, Thomas Huizinga ⁵, CF Allaart ⁷, René Toes ⁵, Georg Schett ⁸ and Diane van der Woude ¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ³Inova Diagnostics, San Diego, CA, ⁴University of Muenster, Muenster, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Haga Ziekenhuis, The Hague, Netherlands, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁸Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: The ability to accurately predict whether RA patients will flare following DMARD-tapering would open doors in clinical decision-making for achieving drug-free remission (DFR). Calprotectin…
Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Julio Ramirez¹, Andrea Cuervo Aguilera ², Raquel Celis ³, Virginia Ruiz-Esquide ³, Raul Castellanos-Moreira ⁴, Jose Gomez-Puerta ⁵, Raimon Sanmarti ⁵ and Juan Cañete ⁵, ¹Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Hospital Clínic Barcelona, Spain, Barcelona, Spain, ³Hospital Clínic, Barcelona, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…
Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting
Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Daniel Solomon¹, Robert Glynn ², Elizabeth Karlson ³, Fengxin Lu ³, Cassandra Corrigan ³, Joshua Colls ³, Chang Xu ³, Jean MacFadyen ³, Medha Barbhaiya ⁴, Nancy Berliner ³, Paul Dellaripa ³, Brendan Everett ³, Sara Hammond ³, Meredith Murray ³, Deepak Rao ³, Susan Ritter ⁵, Anna Rutherford ⁵, Jeffrey Sparks ³, Jacklyn Stratton ⁵, Dong Suh ³, Sara K. Tedeschi ⁶, Kathleen Vanni ³, Nina Paynter ⁵ and Paul Ridker ⁵, ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Harvard Medical School - Boston, MA, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
Abstract Number: 1891 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis
Priyanka Iyer ¹, Yubo Gao ², Saket Girotra ², Jeffrey Curtis ³, Mary Vaughan-Sarrazin ⁴ and Namrata Singh⁴, ¹University of Iowa, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa city, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Iowa, Iowa City
Background/Purpose: Hydroxychloroquine (HCQ) has known immunomodulatory effects and mechanistic actions that may provide cardioprotective effects. To date, cardiovascular (CV) outcomes in elderly patients receiving HCQ…
Abstract Number: 1892 • 2019 ACR/ARP Annual Meeting
Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Lang Chen ⁴, Qufei Wu ², Fenglong Xie ⁵ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The impact of immunosuppression on post-operative outcomes in rheumatoid arthritis (RA) has primarily been studied in patients undergoing joint replacement surgery. We aimed to…
Abstract Number: 1893 • 2019 ACR/ARP Annual Meeting
Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA
Background/Purpose: Chronic inflammation yields higher risk of cardiovascular events (CVE) in patients with rheumatoid arthritis (RA). We recently reported that occult atherosclerosis burden on coronary…
Abstract Number: 1894 • 2019 ACR/ARP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study
Lingyi Li¹, Na Lu ¹, Diane Lacaille ², Hui Xie ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) compared…
Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…
Abstract Number: 1896 • 2019 ACR/ARP Annual Meeting
Breastfeeding in Women with Rheumatic Diseases
Naira Ikram¹, Amanda Eudy ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: For many women, breastfeeding is a central aspect of motherhood, but many worry that their rheumatic disease or treatment will interfere. Fortunately, most anti-rheumatic…
Abstract Number: 1897 • 2019 ACR/ARP Annual Meeting
Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
Martín Valdez-López¹, Jonathan Campos-Guzmán ¹, Ana Barrera-Vargas ², Samuel Govea-Peláez ¹, Diana Gómez-Martín ¹, Jorge Alcocer-Varela ¹, Eduardo Aguirre-Aguilar ¹, Diana Padilla-Ortíz ³ and Javier Merayo-Chalico ¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Universidad De La Sabana, Bogotá, Cundinamarca, Colombia
Background/Purpose: Although SLE is uncommon in men, the disease is usually more severe and requires more aggressive immunosuppression in male patients. There are multiple studies…
Abstract Number: 1898 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study
Signe Knudsen¹, Julia Simard ², Jakob Christensen ³, Thomas Lauersen ⁴, Bent Deleuran ⁵ and Bodil Bech ¹, ¹Department of Public Health, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ²Stanford University School of Medicine, Palo Alto, CA, ³Department of Neurology, Aarhus University Hospital & The National Center for Register-based Research, Aarhus University, Denmark, Aarhus, Denmark, ⁴The National Center for Register-based Research, Department of Economics and Business Economics, Business and Social Science, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁵Department of Biomedicine; Department of Rheumatology, Aarhus University, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) during pregnancy is a risk factor for several adverse pregnancy and child outcomes. Studies have found higher incidences of neurological and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].